

**PROTOCOL CODE: MYDARBD (IV Cycle 2+)**

(Page 1 of 3)

**DOCTOR'S ORDERS**

Ht \_\_\_\_\_ cm Wt \_\_\_\_\_ kg BSA \_\_\_\_\_ m<sup>2</sup>
**REMINDER:** Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form

**DATE:**
**To be given:**
**Cycle #:**

Date of Previous Cycle: \_\_\_\_\_

**\*\*\*\*Ensure Red Blood Cell Phenotype and Group and Screen for all patients prior to Cycle 1\*\*\*\***
☐ Delay treatment \_\_\_\_\_ week(s)

☐ **CBC & Diff** day of treatment

Proceed with all medications for entire cycle as written, if within 96 hours of Day 1: **ANC greater than or equal to 0.5 x 10<sup>9</sup>/L, platelets greater than or equal to 50 x 10<sup>9</sup>/L, total bilirubin less than or equal to 1.5 x upper limit of normal, and eGFR or creatinine clearance per protocol**

Dose modification for: ☐ **Hematology:** \_\_\_\_\_ ☐ **Other Toxicity:** \_\_\_\_\_

Proceed with treatment based on blood work from \_\_\_\_\_

**CHEMOTHERAPY:**
☐ **CYCLOPHOSPHAMIDE – Cycles 2 to 8** (☐ **Cycle 9 onwards optional**)

☐ cyclophosphamide 500 mg PO once weekly in the morning on Days 1, 8, 15, and 22. Dispense \_\_\_\_\_ cycles.  
OR

☐ cyclophosphamide \_\_\_\_\_ mg PO once weekly in the morning on Days \_\_\_\_\_ Dispense \_\_\_\_\_ cycles.  
OR

☐ cyclophosphamide 50 mg PO once in the morning every 2 days for \_\_\_\_\_ doses. Dispense \_\_\_\_\_ cycles

**BORTEZOMIB – Cycles 2 to 8**

- Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily

bortezomib ☐ 1.5 mg/m<sup>2</sup> or ☐ 1.3 mg/m<sup>2</sup> or ☐ 1 mg/m<sup>2</sup> or ☐ 0.7 mg/m<sup>2</sup> or ☐ 0.5 mg/m<sup>2</sup> (select one) x BSA = \_\_\_\_\_ mg  
subcutaneous injection weekly on Days 1, 8, 15, and 22

**STEROID:** RN to use patient's therapeutic steroid (if applicable) as pre-med for daratumumab - refer to protocol

**Cycles 2 to 8** (☐ **Cycle 9 onwards optional**)

☐ dexamethasone ☐ 40 mg or ☐ 20 mg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, OR

☐ dexamethasone \_\_\_\_\_ mg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, OR

☐ predniSONE \_\_\_\_\_ mg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning

☐ No steroid

**DOCTOR'S SIGNATURE:**
**SIGNATURE:**
**UC:**

# **PROTOCOL CODE: MYDARBD (IV Cycle 2+)**

(Page 2 of 3)

**DATE:**

**\*\*Have Hypersensitivity Reaction Tray and Protocol Available\*\***

## **DARATUMUMAB**

- Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily

**DARATUMUMAB PREMEDICATIONS:** Patient to take own supply. RN/Pharmacist to confirm.

**dexamethasone** as ordered in steroid section

☐ **montelukast 10mg** PO prior to each daratumumab

**acetaminophen 650 mg** PO prior to each daratumumab. Repeat **acetaminophen 650 mg** PO every 4 hours when needed

Select one of the following:

☐ **loratadine 10 mg** PO prior to each daratumumab, then **diphenhydrAMINE 50 mg** IV every 4 hours when needed

**OR**

☐ **diphenhydrAMINE 50 mg** ☐ PO or ☐ IV prior to each daratumumab. Repeat **diphenhydrAMINE 50 mg** IV every 4 hours when needed

## **DARATUMUMAB**

☐ **CYCLE 2, Days 1, 8, 15, and 22:**

daratumumab 16 mg/kg x \_\_\_\_\_ kg = \_\_\_\_\_ mg IV in 500 mL NS (use 0.2 micron in-line filter)

☐ **CYCLE 3 to 4, Days 1 and 15:**

daratumumab 16 mg/kg x \_\_\_\_\_ kg = \_\_\_\_\_ mg IV in 500 mL NS (use 0.2 micron in-line filter)

☐ **CYCLES 5 to 8, Day 1:**

daratumumab 16 mg/kg x \_\_\_\_\_ kg = \_\_\_\_\_ mg IV in 500 mL NS (use 0.2 micron in-line filter)

☐ **CYCLE 9 onwards, Day 1:**

daratumumab 16 mg/kg x \_\_\_\_\_ kg = \_\_\_\_\_ mg IV in 500 mL NS (use 0.2 micron in-line filter) x \_\_\_\_\_ cycle(s) (max 3 cycles)

### **Infusion rate for cycle 2 onwards: Physician to determine rate of infusion**

***If no reaction in the previous infusion or reaction is Grade 2 or less:***

☐ Start at 200 mL/h. If no infusion - related reactions after 30 minutes, infuse the remainder at 450 mL/h (Rapid infusion)

***OR If reaction in the previous infusion is Grade 3:***

☐ Start at 100 mL/h. If no infusion-related reactions after 60 minutes, increase by 50 mL/h every 60 minutes to a maximum rate of 200 mL/h. Refer to protocol for modified starting rate if previous infusion reactions were experienced during infusion rate of greater than or equal to 100 mL/h (Slow infusion)

### **Vitals monitoring:**

Vital signs immediately before the start, at the end of the infusion and as needed. Observe patient for 30 minutes after infusion (vitals and observation post-infusion not required after 3 treatments with no reaction).

**DOCTOR'S SIGNATURE:**

**SIGNATURE:**

**UC:**

**PROTOCOL CODE: MYDARBD (IV Cycle 2+)**

(Page 3 of 3)

DATE:

**RETURN APPOINTMENT ORDERS**

For Cycles 3 to 8 book chemo on Days 1, 8, 15, 22

For Cycles 9 and subsequent, book chemo on Day 1

- ☐ Return in **four** weeks for Doctor and Cycle \_\_\_\_\_
- ☐ Return in **eight** weeks for Doctor and Cycles \_\_\_\_\_ and \_\_\_\_\_. Book chemo x 2 cycles.
- ☐ Return in **twelve** weeks for Doctor and Cycles \_\_\_\_\_, \_\_\_\_\_ and \_\_\_\_\_. Book chemo x 3 cycles
- ☐ Last Cycle. Return in \_\_\_\_\_ week(s).

**CBC & Diff, creatinine, urea, sodium, potassium, total bilirubin, ALT, alkaline phosphatase, calcium, albumin, LDH, random glucose, serum protein electrophoresis and serum free light chain levels every 4 weeks**

- ☐ Urine protein electrophoresis every 4 weeks
- ☐ Immunoglobulin panel (IgA, IgG, IgM) every 4 weeks
- ☐ Beta-2 microglobulin every 4 weeks
- ☐ CBC & Diff Days 8, 15, 22
- ☐ Creatinine, sodium, potassium Days 8, 15, 22
- ☐ Total bilirubin, ALT, alkaline phosphatase Days 8, 15, 22
- ☐ Random glucose Days 8, 15, 22
- ☐ Calcium, albumin Days 8, 15, 22
- ☐ **HBV viral load** prior to next cycle
- ☐ See general orders sheet for additional requests
- ☐ Other tests:
- ☐ Consults

**DOCTOR'S SIGNATURE:**
**SIGNATURE:**
**UC:**